SITEMAP
-
Science
- Cutting Edge Science
- Inspiration and Innovation
- Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
-
Asthma
-
Cutting Edge Science
- 2021
-
Innovation
- How do you balance the cost of Biologics with the value they can bring to patients?
- What challenges do you face when treating patients with Type 2 inflammation?
- How do you choose the right Biologic for a particular Asthma patients?
- Why is it important to look for Type 2 inflammation in patients with Asthma?
- How Type 2 inflammation affect patients with Asthma?
- When do you discuss Biologic treatment with your Asthma patients?
- 2022
- 2023
-
2024
- Severe Asthma Biomarker's
- The Vital Role of Lung Function in Asthma Care
- Sever Asthmatic patients with OCS
- Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
- Fractional exhaled nitric oxide (Feno)
-
Airway Hyperresponsiveness
in Asthma - ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
- 2025
-
Cutting Edge Science
- Atopic Dermatitis
-
Cardiovascular
-
Atherothrombosis
-
Cutting Edge Science
- Innovation
-
2022
- Adherence and persistence analysis in patients treated with DAPT
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
-
2023
-
Cutting Edge Science
-
Dyslipidemia
-
Cutting Edge Science
-
2021
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- ESC/EAS 2019 Guidelines for the management of dyslipidaemias
- Switching From Statin Monotherapy to Statin/Ezetimibe Combination
- Long-term effectiveness and safety of statin therapy
- The ACTE Study
- Optimal use of LLT after ACS
- The Explorer Study
- The ROSETTE Study
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
-
Innovation
- 2022
- Improving Lipid Management for Patients Post-ACS
- Lipid management in patients with ACS/ASCVD
- Act Now for Your ACS Patients: Summary
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- Atherosclerosis: Identifying risks and improving outcomes
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Statin/ezetimibe SPC for better adherence to LLT
- Act Now for Your ACS Patients: Optimize Your ACS Pathway
- Act Now for Your ACS Patients: Patient Identification
- Identifying and treating patients with high Lipidaemia risk post-ACS
-
2022
- Atherosclerotic Cardiovascular Disease Risk Assessment
- CV Risk management in T1DM using guidelines
- LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
- Statin/Ezetimibe Combination VS Statin Monotherapy
- Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
- ESC Lp(a) in Clinical practice EAS Consensus statement
- Should we encourage earlier and broader use of combination therapies in dyslipidemia?
- Relationship Between LDL-C LLTs and Risk of Stroke
- Public health recommendations for Lp(a) measurement
- Event rates and Risk Factors for Recurrent CV Events
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- Prescription Trends of Oral Non-Statin LLTs and Their Effects on LDL-C
- LLTs Exposure Time and Major Vascular Risk Reduction
- LDL-C The Only Causal Risk Factor for ASCVD
- Single-Pill Combinations in Dyslipidemia
- PCSK9i and Prevention of CVD
- PCSK9 inhibitors and ACS
- Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
- PCSK9 Inhibitors in Cardiovascular Disease
-
2023
-
2021
-
Cutting Edge Science
- Hypertension
-
Thrombosis
-
Atherothrombosis
- Chronic Obstructive Pulmonary Disease
-
Diabetes
-
Cutting Edge Science
-
2021
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- Basal Insulin and Beyond: Advanced Therapies for Type 2 Diabetes
- A Cross-Sectional Analysis of Glycemic Control in Elderly People with Type 2 Diabetes Attending Primary Health Care Unit
- Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
- Effectiveness of continuous glucose monitoring in adults with Type 2 diabetes treated with basal insulin
- Reducing risk of severe hypoglycemia - iNPHORM Study
- The Bright Study
- Unmet needs in adults with T2D receiving premixed insulin
- Prevalence of Diabetes in Children and Adolescents
- Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D
- Hospitalization Rates for Acute Diabetes Complications Before and After Flash Glucose Monitoring Initiation Among People with Type 1 or Type 2 Diabetes in France: The Relief Study
-
Innovation
- 2022
- ATTD 2021: Patients’ profiles for digital tools
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
- The InRange Study
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Summary of SAGE study on Adults with T1DM
- Diabetes your type: Testimonial by Dr. Hussein
- Diabetes your type: Testimonial by Dr. Nadia
- The SoliRam observational study
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Diabetes Your Type: Testimonial by Dr. Bassam
- ADA 2021: Solimix Trial Summary
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- SoliMix Study Results Summary
- T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
- T1DM Mini-Series: Edition JUNIOR trial results
- T1DM Mini-Series: How does Hypoglycaemia impact the life of people with T1 Diabetes?
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
- T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
- T1DM Mini-Series: The main challenge for the kids and adolescents with T1
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- Challenges associated with commonly-used insulin advancement options
- EVOLUTION: RWE from Saudi Arabia
- Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
- Treatment simplification of complex insulin regimens in T2D
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- EMPOWER Study in Saudi Arabia
-
2022
- Single injectable treatment may not be enough to get T2DM patient to Glycemic goal
- Selecting a CGM device
- Limitations with the use of BGM
- Commercially available CGM systems
- Case 2 T1D
- Case 1 T2D
- Benefits of using CGM vs BGM
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
- Closed-loop insulin delivery during exercise in people with T1D
- Diabetes management during Ramadan
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- Additional signals
- BI hormonal CL systems
- Development of Insulin
- Enhanced algorithms
- Improved usability
-
Single Injectable Treatment May Not Be Enough To Get T2dm Patient To Glycemic Goal
- 2023
-
2024
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
- An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy
- Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps
- Need to redefine the treatment paradigm Post OAD
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- The Evolving Role of Treatment and Technology in Diabetes Care
- SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy
- Time-in-Range: A Key Determinant of Quality of Life
- SoliD: Redefine Treatment Paradigm Post-OAD
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- 2025
-
2021
-
Cutting Edge Science
- Eosinophilic Esophagitis
- Multiple Myeloma
-
Multiple Sclerosis
-
Cutting Edge Science
-
2022
- A promising biomarker in MS: Neurofilament light chain
- How old is your brain?
- Exercise as ”medicine” in the treatment of MS
- MS Updates
- Cognitive training – A curse or a blessing?
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- Measuring brain atrophy. What can be done and where are we heading?
- Cognitive decline – The invisible burden of MS?
- Falling chronically ill – How do I cope and move forward?
- The importance of deep grey matter in MS
- The reason for MS – beyond focal inflammation
- Why has our brain suddenly become of interest?
- Innovation
-
2023
- 2024
- 2025
-
2022
-
Cutting Edge Science
-
Nasal Polyps
-
Cutting Edge Science
- 2021
- 2022
-
2023
- Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?
- What does patient empowerment mean for your treatment plan?
- Hear From An Expert On What Have You Learned From Your Experience With Biologics?
- Hear From An Expert On The Type 2 Immune Response And Inflammation
- Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
- Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.
- Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?
- Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery
- Hear From An Expert On How Do You Manage Treatment Compliance Issues In Patients With Crs With Nasal Polyps?
- “Smell—we call it the Cinderella of the senses"
- What can biologic treatment do for patients with CRS with nasal polyps?
- Hear From An Expert On Identifying Patients Who Are Appropriate Candidates For Biologic Treatment
- Hear From An Expert On What Are The Main Challenges In Treating Patients With Crs With Nasal Polyps?
- "It really has changed the way I manage our patients"
- Hear From An Expert On How Can You Limit The Effects Of Systemic Steroid Use For Patients With Crs With Nasal Polyps?
- Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
- You can imagine more than 90% of CRSwNP patients losses their ability's of smell
- Hear From An Expert On How Do You Address Patients' Concerns About Sinus Surgery?
- Hear From An Expert On What Does The Future Of Treatment Look Like For Crs With Nasal Polyps?
- How does Dupixent help recover smell?
- Hear From An Expert On What Does Dupixent Bring To Your Practice?
- NPS improvement with Dupixent over time
- Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
- 2024
-
2025
- IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
- Loss of Smell Is a Key Symptom in CRSwNP
- Loss of Smell Improvement in Patients With CRSwNP
- EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
-
Cutting Edge Science
- Neurological Disorders
-
Prurigo Nodularis
-
Cutting Edge Science
-
2022
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
- Mechanism of Prurigo Nodularis Disease
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- There is significant unmet need in the management of PN¹
-
2022
-
Cutting Edge Science
-
Rare Diseases
-
Cutting Edge Science
-
Innovation
- 2022
- Bone Monitoring Guidelines in Gaucher Disease Video
- Diagnostic Algorithm for Gaucher Disease in Adult
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- Pompe video
- Lysosomal Storage Diseases from Neurology Perspective
- Professor Fatma Al-Jasmi video on ASMD
- Professor Moeen Al Sayed video on ASMD
- Professor Tawfeq Ben Omran video on ASMD
- Their Stories shaped them like Pearls
- Diagnostic challenges of LOPD
- Early diagnosis and management of IOPD
- LSDs overview
- How is LSDs prevalence & epidemiology different in our region?
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- What are Lysosomal Storage disorders?
- Fabry Disease from Cardiology Perspective
- When shall we think of a rare disease from Neurological perspective
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- IOPD Challenges
- Have you considered Pompe Disease?
- Social stigma
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- The Stigma of Rare Diseases
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Multidisciplinary approaches in Rare Disease Patient management
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- Gaucher disease awareness month video
- How To Diagnose LSDs?
- Better care for Fabry
- 2022
-
2023
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Fabry
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Pompe
- Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- Gaucher
-
2024
- ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
- BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
- DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
- Consensus Guidelines for the Clinical Management of ASMD
- Pompe Care Podcast Series
- Navigating the Pompe Disease Journey
- Impact of symptoms and risk of ASMD on patients and caregivers
- Differential diagnostics for ASMD in patients suspected to have GD
- What Are the Signs and Symptoms of ASMD?
- ASMD
- Legacy Video for Rare Disease Academy
- Uncover ASMD and GAUCHER
- 2025
-
Innovation
-
Cutting Edge Science
- Vaccines
- Legal Notice
- Cookie Policy
- Privacy Policy
- Search
- My Account
- Incomplete Profile Notice
- Incomplete Profile
- Patient Support
- Error 404
- Qatar Contact Details
- Events Calendar
-
Products
- Adacel®
- Aubagio®
- Beyfortus®
- Cablivi®
- Cerezyme®
- Clexane®
- Dupixent®
- Fabrazyme®
- Lemtrada®
- Myozyme®
- Nexviazyme
- Plavix®
- Praluent®
- Renvela®
- Solian®
- Soliqua®
- Tavanic®
- Toujeo®
- Xatral®
- Xenpozyme®
- Zympass®
-
Events
- Events
- Anti Infectives
-
Cardiovascular
- 2022
- 2023
-
2021
- VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
- VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- Dyslipidemia Webinars: Optimizing Dyslipidemia management
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
-
Diabetes
- 2021
-
2022
- Innovation of Iglarlexi in Intensification
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Diabetes Guidelines in Ramadan
- Type 2 Diabetes Cost Effective Management
- Navigate new destinations in diabetes management
- Leveraging Time-In-Range to Improve Patient Experience
- Nutrition and Insulin management in Ramadan
- Ultimate Need for Intensification
- Innovation of Iglarlexi in Intensification
- Diatour Inquiry Form
-
2023
- Treating Type 2 Diabetes Today - How is it Changing?
- Cardiometabolic Approach in Diabetes Management
- GAED 2023
- Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- Safe & Smart - Dr. Khudhair
- Safe & Smart - Dr. Nabil
- Safe & Smart - Dr. Kalra
- World Diabetes Day
- Safe & Smart - Dr. Salah
- Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- 2024
- Sitemap
- Registration